Affiliate disclosure: As an Amazon Associate, I earn from qualifying purchases. I only recommend products with real scientific evidence behind them, and I'm upfront about where the evidence is thin.
What your coronary calcium score actually means (and what actually lowers it)
If you've had a coronary artery calcium (CAC) scan and watched the number climb on a repeat scan, you might assume you're doing something wrong. The honest answer is often the opposite: a rising score can mean your arteries are getting safer, not more dangerous. That's not how the test is marketed.
What the research actually shows
Start with what the score measures. According to PubMed, a 2018 review in the Journal of the American College of Cardiology, covering up to 15 years of outcomes data, describes CAC as a highly specific marker of coronary atherosclerosis used mainly to guide statin and aspirin decisions in people without symptoms (Greenland et al., 2018, DOI). It doesn't measure how "clogged" your arteries are right now, it measures calcium already laid down: a permanent record, not a live readout.
The distinction that matters clinically became clear only recently: density, not total volume, predicts risk. According to PubMed, a 2024 meta-analysis in JACC: Cardiovascular Imaging, pooling over 21,000 patients followed up to 17 years, found denser calcium meant a 20% lower event risk per standard deviation increase, independent of total volume (Yong et al., 2024, DOI). Dense calcium is stable, "healed" plaque; diffuse, low-density calcium mixed with soft plaque is what ruptures.
That's why statins, the best-evidenced intervention once your score crosses treatment threshold, don't lower your number and can raise it. According to PubMed, a 2025 study in the International Journal of Cardiovascular Imaging, tracking 316 patients rescanned after 3.8 years on average, found statin-treated patients with mixed-density calcium saw significantly greater increases in calcium volume across every density category, including the densest, most stable one (Giovannucci et al., 2025, DOI). Researchers call this a shift toward a "more stable phenotype," not disease worsening. A rising score on a statin can be the drug working.
Exercise doesn't move the score down either. According to PubMed, a 2024 study in JAMA Cardiology, following nearly 8,800 adults for almost eight years on average, found physical activity volume wasn't associated with CAC progression, active or not (Shuval et al., 2024, DOI). An earlier 2021 study in Heart, covering 25,000-plus adults over five years, found the most active group's scores rose faster than the least active group's (Sung et al., 2021, DOI). Fitness protects you through mortality and event-risk pathways, just not by shrinking this number.
Vitamin K2, marketed on the theory it "directs calcium away from arteries," has been tested directly and failed. According to PubMed, a 2022 randomized, double-blind trial in Circulation gave 365 men with valve calcification either vitamin K2 (720mcg/day) plus vitamin D or placebo for two years. Calcification progressed identically in both groups, with no significant difference in coronary calcium progression either, despite the supplement doing its intended biochemical job (Diederichsen et al., 2022, DOI). It's a rigorous negative trial worth knowing before spending on K2 for this.
The more encouraging evidence sits in soft, non-calcified plaque the score can't capture. According to PubMed, a 2020 case-control study in Clinical Nutrition, using CT angiography on 106 risk-matched patients, found omega-3 users had significantly less high-risk, lipid-rich plaque (3.8% versus 32% prevalence) and lower non-calcified plaque burden than controls, even with similar CAC scores (Feuchtner et al., 2020, DOI). Omega-3 won't move your CAC number, but the plaque it's acting on arguably matters more. NOW Foods' Omega-3 softgels, molecularly distilled with 180mg EPA/120mg DHA per softgel, deliver a clinically relevant dose without a prescription product.
What this means for you
A higher score on a repeat scan isn't proof your lifestyle changes failed. Ask your doctor about calcium density, not just the total, and confirm you're on interventions with real trial support: statins if your score crossed threshold, and attention to non-calcified plaque a CAC scan alone won't show. Skip vitamin K2 for this specific purpose. Keep exercising for every other reason it matters, just not this one. If you take fish oil, its case rests on soft-plaque stabilization, not a lower CAC report.
The biotype angle
This cuts across biotypes, since calcification tracks with age, genetics, and long-term LDL exposure more than body composition. Endomorphs managing higher cardiometabolic risk are the group most likely to have a CAC scan ordered, and the ones who benefit most from knowing a rising score isn't automatically bad news. Ectomorphs and mesomorphs training hard shouldn't read the exercise findings as license to slack off; fitness protects through different mechanisms than CAC.
The honest verdict
Almost nothing lowers a coronary calcium score once it's there, and some things that should, statins and exercise, associate with the opposite. That's not a reason to ignore the test, it's a reason to stop treating the raw number as the target. Density beats volume, statins working can look like the score rising, and the plaque that causes heart attacks is a different conversation than "how do I get this number down." Omega-3's evidence lives there, not on your CAC report.
Want a nutrition and training approach built around your actual cardiovascular risk profile, not a single number on a scan?
→ Get the free Biotype Guide
References:
1. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018. DOI: 10.1016/j.jacc.2018.05.027. PMID: 30025580.
2. Yong Y, Giovannucci J, Pang SN, et al. Coronary Artery Calcium Density and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2024. DOI: 10.1016/j.jcmg.2024.07.024. PMID: 39243235.
3. Giovannucci J, Shanbhag A, Hong W, et al. Impact of statins on progression of coronary artery calcium composition and density as assessed by noncontrast CT. Int J Cardiovasc Imaging. 2025. DOI: 10.1007/s10554-025-03561-0. PMID: 41201709.
4. Shuval K, Leonard D, DeFina LF, et al. Physical Activity and Progression of Coronary Artery Calcification in Men and Women. JAMA Cardiol. 2024. DOI: 10.1001/jamacardio.2024.0759. PMID: 38748444.
5. Sung KC, Hong YS, Lee JY, et al. Physical activity and the progression of coronary artery calcification. Heart. 2021. DOI: 10.1136/heartjnl-2021-319346. PMID: 34544807.
6. Diederichsen ACP, Lindholt JS, Möller S, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation. 2022. DOI: 10.1161/CIRCULATIONAHA.121.057008. PMID: 35465686.
7. Feuchtner G, Langer C, Barbieri F, et al. The effect of omega-3 fatty acids on coronary atherosclerosis quantified by coronary computed tomography angiography. Clin Nutr. 2020. DOI: 10.1016/j.clnu.2020.07.016. PMID: 32778459.
